
Valo Health and Novo Nordisk Sign Partnership to Harness Valo Health AI-driven Drug Discovery Tools
Valo Health, Inc. and Novo Nordisk A/S have announced a collaboration to discover and develop innovative treatments for cardiometabolic diseases utilizing Valo’s extensive human dataset and artificial intelligence (AI) capabilities. This partnership will harness Valo’s Opal Computational Platform™, which includes access to real-world patient data, AI-driven small molecule discovery, and the Biowire® human tissue modeling platform to expedite the drug discovery and development process. Valo’s preclinical capabilities will aid in identifying and validating novel druggable targets, developing drug candidates, and predicting compound safety and efficacy.
As part of the agreement, Novo Nordisk is licensing three preclinical drug discovery programs in cardiovascular diseases developed by Valo using the Opal Computational Platform™. Valo will receive an upfront payment of $60 million and a potential near-term milestone payment. Moreover, Valo is eligible to receive milestone payments for up to 11 programs, totaling up to $2.7 billion, along with research and development funding and potential royalty payments.
This collaboration combines the strengths of both organizations in human data, genetics, and expertise in cardiometabolic diseases. The use of AI and machine learning in drug discovery and development holds the potential to advance the understanding of target biology and lead to the development of therapeutics for patients with cardiometabolic conditions. This partnership aims to leverage human genetic and longitudinal patient data to derive novel insights in cardiovascular disease, with a focus on improving patient outcomes.
Valo Health, Inc. is a technology company that utilizes large-scale data and AI-driven computation to discover and develop therapeutics, with a particular focus on cardiovascular, metabolic, renal, oncology, and neurodegenerative diseases. The Valo’s Opal Computational Platform™, uses machine learning, tissue biology, and patient data to facilitate drug discovery and development. The company recently signed an agreement through its Logica collaboration with Charles River Laboratories with Related Sciences to evaluate high potential therapeutic candidates in their portfolio. Charles River Laboratories and Valo Health announced their strategic collaboration in Jan. 2022. The company has also partnered with Tara Biosystems to use their 3-dimensional tissue engineering and cardiovascular disease modeling capabilities with Valo’s Opal Computational Platform.
Novo Nordisk A/S, headquartered in Denmark, is a leading global pharmaceutical company with a mission to defeat serious chronic diseases, particularly in the field of diabetes. The company currently has global pharmaceutical sales of almost $30 billion per year and represents the largest partner for Valo Health to date.
This collaboration further signifies the importance of integrating AI and comprehensive patient data into the drug discovery and development process to accelerate the development of life-changing medications while reducing costs and time.